Website intended for a NZ health professional readership
How effective are psychosocial interventions for smoking cessation in patients with coronary heart disease (CHD)?
After a cardiac event about 30% to 50% of smokers with CHD quit without professional help. Additional psychosocial interventions showed a superior quitting rate (NNT* 14.9) compared to usual care in the short-term (six to 12 months). Long-term (>12 months) follow-up showed an attenuation in the benefit of psychosocial interventions for smoking cessation. Interventions consisted of behavioural therapeutic approaches, telephone support and self-help material. Brief interventions were not effective. Adverse effects were not reported in any trial.
*NNT = number needed to treat to benefit one individual.
The trials mostly included older male patients with CHD, predominantly myocardial infarction. Heterogeneity between trials was substantial.
Smoking increases the risk of developing atherosclerosis but also acute thrombotic events. Quitting smoking is potentially the most effective secondary prevention measure and improves prognosis after a cardiac event, but more than half of these patients continue to smoke, and improved cessation aids are urgently required.
Barth J et al. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Reviews, 2015, Issue 7. Art. No.: CD006886.DOI: 10.1002/14651858. CD006886.pub2. This review contains 40 studies involving 7,682 participants.
Cochrane Systematic Reviews for primary care practitioners
Developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the Ministry of Health and New Zealand Doctor. PEARLS are meant for educational use and not to guide clinical care. New Zealanders can access the Cochrane Library free via www.cochrane.org.nz
Prostate cancer consultations are common in primary care and there is no one approach to testing and treatment that fits all patients. Urologist Simon van Rij discusses the key considerations and options for personalised care, appropriate investigation and treatment
![Amtech Medical marketing manager Jasmine Anderson and Ebos Health senior account manager Sageran Naidoo [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/2%28a%29.JPG?itok=Jdm5dZdg)
![Medtech CEO Geoffrey Sayer and MyPractice founder and Auckland-based specialist GP Ashwin Patel [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/3%28a%29.JPG?itok=LdPwyQwJ)
![Mahoe Medical Centre administration managers Ashlee Herbert and Julie-Ann Foreman [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/4%28b%29.JPG?itok=_NUoSaY2)
![Broadway Health Management Centre administrators Stef LeGros and Julie Johnson [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/5%28b%29.JPG?itok=Q5P9RMB1)
![Newtown Union Health Service administrators Tunisia Pohatu and Waty Arief-Macher [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/6%28a%29.JPG?itok=ttzKlXLf)
![SR Referrals client support staff Athulya Mohandas and Shona Cribb and support manager Amy Moyle [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/7%28a%29.JPG?itok=11zaUO5S)
![Webtools implementation specialist Hannah Laurie and head of marketing Bridget Holland [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/11%28b%29.JPG?itok=4Q_1zwTg)
![DataCraft Analytics operations manager Rachel Blanch and managing director Jayden Macrae [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/1%28c%29.JPG?itok=ipS4z2aa)
![Collaborative Aotearoa CEO Jess Morgan-French, Three Rivers Medical general manager Michelle Te Kira and Third Age Health chief executive Tony Wai [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/10%28a%29.JPG?itok=t2X4h7nC)
